title: Long-Term Breast Cancer Patient Outcomes After Adjuvant Radiotherapy Using Intensity-Modulated Radiotherapy or Conventional Tangential Radiotherapy.
abstract: The aim of the article is to analyze breast cancer patient clinical outcomes after long-term follow-up using intensity-modulated radiotherapy (IMRT) or conventional tangential radiotherapy (cRT). We retrospectively reviewed patients with stage 0-III breast cancer who received breast conserving therapy between April 2004 and December 2007. Of the 234 patients, 103 (44%) were treated with IMRT and 131 (56%) were treated with cRT. A total prescription dose of 45 to 50 Gy (1.8-2 Gy per fraction) was delivered to the whole breast. A 14 Gy boost dose was delivered in 7 fractions. The median follow-up was 8.2 years. Five of 131 (3.8%) cRT-treated patients and 2 of 103 (1.9%) IMRT-treated patients had loco-regional failure. The 8-year loco-regional failure-free survival rates were 96.7% and 97.6% (P = 0.393) in the cRT and IMRT groups, respectively, whereas the 8-year disease-free survival (DFS) rates were 91.2% and 93.1%, respectively (P = 0.243). Patients treated with IMRT developed ≥ grade 2 acute dermatitis less frequently than patients treated with cRT (40.8% vs 56.5%; P = 0.017). There were no differences in late toxicity. IMRT reduces ≥ grade 2 acute skin toxicity. Local control, DFS, and overall survival were equivalent with IMRT and cRT. IMRT can be considered a standard technique for breast cancer treatment.
authors.affiliation: From the Department of Radiation Oncology (J-FY, C-SL, H-LC, C-MC, C-HL, C-YF, C-CT, W-YH), Tri-Service General Hospital; School of Public Health (M-SL), National Defense Medical Center; and Institute of Clinical Medicine (W-YH), National Yang-Ming University, Taipei, Taiwan.
authors.forename: Jen-Fu
authors.initials: JF
authors.lastname: Yang
authors.forename: Meei-Shyuan
authors.initials: MS
authors.lastname: Lee
authors.forename: Chun-Shu
authors.initials: CS
authors.lastname: Lin
authors.forename: Hsing-Lung
authors.initials: HL
authors.lastname: Chao
authors.forename: Chang-Ming
authors.initials: CM
authors.lastname: Chen
authors.forename: Cheng-Hsiang
authors.initials: CH
authors.lastname: Lo
authors.forename: Chao-Yueh
authors.initials: CY
authors.lastname: Fan
authors.forename: Chih-Cheng
authors.initials: CC
authors.lastname: Tsao
authors.forename: Wen-Yen
authors.initials: WY
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011855:Radiodermatitis / Q000209:etiology; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors